LaFleur & Godfrey LLC decreased its position in AbbVie Inc. (NYSE:ABBV – Free Report) by 5.1% during the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 71,689 shares of the company’s stock after selling 3,873 shares during the period. AbbVie comprises approximately 2.0% of LaFleur & Godfrey LLC’s portfolio, making the stock its 15th biggest holding. LaFleur & Godfrey LLC’s holdings in AbbVie were worth $16,380,000 at the end of the most recent quarter.
Other hedge funds and other institutional investors have also made changes to their positions in the company. Wellington Management Group LLP grew its stake in AbbVie by 457.4% in the 3rd quarter. Wellington Management Group LLP now owns 10,536,901 shares of the company’s stock valued at $2,439,714,000 after acquiring an additional 8,646,424 shares during the last quarter. Vanguard Group Inc. raised its position in AbbVie by 1.7% during the fourth quarter. Vanguard Group Inc. now owns 180,779,699 shares of the company’s stock worth $41,306,353,000 after acquiring an additional 3,032,438 shares during the last quarter. Raymond James Financial Inc. lifted its holdings in shares of AbbVie by 41.8% in the second quarter. Raymond James Financial Inc. now owns 9,337,480 shares of the company’s stock valued at $1,733,222,000 after purchasing an additional 2,753,312 shares in the last quarter. Alliancebernstein L.P. lifted its holdings in shares of AbbVie by 31.8% in the third quarter. Alliancebernstein L.P. now owns 7,281,327 shares of the company’s stock valued at $1,685,918,000 after purchasing an additional 1,758,657 shares in the last quarter. Finally, Amundi grew its position in shares of AbbVie by 15.6% in the third quarter. Amundi now owns 10,508,317 shares of the company’s stock valued at $2,418,909,000 after purchasing an additional 1,414,621 shares during the last quarter. Institutional investors and hedge funds own 70.23% of the company’s stock.
Key AbbVie News
Here are the key news stories impacting AbbVie this week:
- Positive Sentiment: Q1 beat and raised guidance spurred a rally: AbbVie reported stronger‑than‑expected Q1 results and lifted 2026 guidance, which pushed the stock higher in early May as investors reassessed growth prospects from Skyrizi, Rinvoq and the pipeline. ABBV Stock Up 5% on Robust Q1 Performance: Time to Buy, Sell or Hold?
- Positive Sentiment: Analyst and retail attention following the quarter: Coverage from Zacks highlights the company as a top‑searched/“trending” stock, reflecting elevated investor interest after the beat — attention that can amplify moves on earnings or guidance news. ABBV Stock Up 5% on Robust Q1 Performance: Time to Buy, Sell or Hold?
- Positive Sentiment: Dividend appeal remains strong: Multiple income‑focused outlets continue to list AbbVie as a high‑yield dividend candidate, supporting demand from dividend investors despite valuation considerations. Want to Collect a High Dividend Every Month? Invest in These 3 Stocks
- Neutral Sentiment: Positive clinical and real‑world data showcased at DDW: AbbVie presented long‑term and real‑world evidence for SKYRIZI (risankizumab) and RINVOQ (upadacitinib) in IBD, which supports the commercial outlook but will take time to materially change revenue trajectory. AbbVie Highlights New Long-Term Data Advancing Treatment Standards in Inflammatory Bowel Diseases (IBD) at 2026 Digestive Disease Week®
- Neutral Sentiment: Industry tech/AI events mention AbbVie involvement: Participation in life‑science AI forums signals digital investment but is unlikely to move near‑term fundamentals. Zifo’s SiEE Boston Summit Charts New Roadmap for ‘Practical AI’ in Life Sciences, Bridging the Gap Between Business Vision and Lab Reality
- Negative Sentiment: Regulatory/manufacturing setback for a wrinkle treatment: The U.S. FDA declined to approve AbbVie’s wrinkle product over manufacturing concerns (reported April 23), a near‑term headwind that can pressure sentiment and highlight execution risk on noncore franchises. US FDA declines to approve AbbVie’s wrinkle treatment due to manufacturing concerns (April 23)
Analyst Upgrades and Downgrades
View Our Latest Research Report on ABBV
AbbVie Stock Down 1.0%
Shares of NYSE:ABBV opened at $206.12 on Wednesday. The company has a market cap of $364.46 billion, a P/E ratio of 101.54, a P/E/G ratio of 0.72 and a beta of 0.32. The business has a fifty day simple moving average of $214.17 and a 200-day simple moving average of $221.34. AbbVie Inc. has a 52 week low of $176.57 and a 52 week high of $244.81.
AbbVie (NYSE:ABBV – Get Free Report) last released its earnings results on Wednesday, April 29th. The company reported $2.65 earnings per share for the quarter, topping the consensus estimate of $2.59 by $0.06. AbbVie had a negative return on equity of 911.57% and a net margin of 5.79%.The firm had revenue of $15 billion for the quarter, compared to the consensus estimate of $14.72 billion. The firm’s revenue for the quarter was up 12.4% compared to the same quarter last year. During the same period in the prior year, the business posted $2.46 earnings per share. Sell-side analysts expect that AbbVie Inc. will post 14.3 earnings per share for the current fiscal year.
AbbVie Announces Dividend
The business also recently declared a quarterly dividend, which will be paid on Friday, May 15th. Shareholders of record on Wednesday, April 15th will be paid a dividend of $1.73 per share. The ex-dividend date of this dividend is Wednesday, April 15th. This represents a $6.92 dividend on an annualized basis and a yield of 3.4%. AbbVie’s dividend payout ratio (DPR) is currently 340.89%.
Insider Buying and Selling
In other AbbVie news, SVP David Ryan Purdue sold 5,230 shares of AbbVie stock in a transaction on Wednesday, March 4th. The shares were sold at an average price of $233.56, for a total value of $1,221,518.80. Following the transaction, the senior vice president owned 2,654 shares in the company, valued at $619,868.24. This trade represents a 66.34% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, EVP Perry C. Siatis sold 22,381 shares of the business’s stock in a transaction on Wednesday, February 25th. The shares were sold at an average price of $230.00, for a total transaction of $5,147,630.00. Following the sale, the executive vice president directly owned 38,137 shares of the company’s stock, valued at $8,771,510. This represents a 36.98% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Company insiders own 0.06% of the company’s stock.
AbbVie Company Profile
AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.
AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.
See Also
Receive News & Ratings for AbbVie Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AbbVie and related companies with MarketBeat.com's FREE daily email newsletter.
